Boston Advisors LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,696 shares of the biopharmaceutical company’s stock after buying an additional 465 shares during the period. Boston Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,798,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. raised its position in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Janus Capital Management LLC raised its position in Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the last quarter. Wellington Management Group LLP raised its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Clearbridge Investments LLC raised its position in Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares during the last quarter. Finally, Harding Loevner LP raised its position in Regeneron Pharmaceuticals by 76.8% in the first quarter. Harding Loevner LP now owns 557,400 shares of the biopharmaceutical company’s stock worth $215,998,000 after buying an additional 242,162 shares during the last quarter. Institutional investors and hedge funds own 67.16% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded up 0.85% during mid-day trading on Friday, hitting $467.98. 549,722 shares of the company’s stock traded hands. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55. The firm has a 50-day moving average of $489.51 and a 200 day moving average of $430.92. The company has a market cap of $49.62 billion, a PE ratio of 46.95 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter last year, the firm earned $2.82 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Boston Advisors LLC” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://stocknewstimes.com/2017/08/19/regeneron-pharmaceuticals-inc-regn-shares-bought-by-boston-advisors-llc-updated-updated.html.
A number of equities analysts have recently commented on REGN shares. Canaccord Genuity upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $375.00 to $484.00 in a research note on Friday, May 5th. Vetr lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 price target on the stock. in a research note on Monday, May 1st. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Piper Jaffray Companies boosted their price target on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research note on Tuesday, June 20th. Finally, BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $495.59.
In related news, Chairman P Roy Vagelos sold 9,295 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the completion of the transaction, the chairman now owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael S. Aberman sold 2,269 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the transaction, the senior vice president now directly owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold 84,404 shares of company stock valued at $40,303,792 in the last three months. 10.40% of the stock is owned by insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
